The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34 CML stem/progenitor cells

Leukemia

Volumn 25, Issue 7, 2011, Pages 1159-1167

  Pellicano, F ^a   Imara, P ^b   Sinclair, A ^a   Helgason, G V ^a   Copland, M ^a   Grant, S ^c   Holyoake, T L ^a,d  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b MASARYK UNIVERSITY   (Czech Republic)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

Author keywords

BMS 214662; CML; HSC; MEK inhibitor; PD184352; TKI

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; BCR ABL PROTEIN; CASPASE 3; CASPASE 8; CASPASE 9; K RAS PROTEIN; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; BLAST CELL CRISIS; CANCER CELL CULTURE; CD34+ T LYMPHOCYTE; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MUTANT; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; STEM CELL; T LYMPHOCYTE;

EID: 79960279190     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.67     Document Type: Article

References (31)

1. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290-293.
2. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824-830.
3. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008; 112: 4808-4817.
4. Hughes T, Branford S. Molecular monitoring of chronic myeloid leukemia. Semin Hematol 2003; 40: 62-68.
5. Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101: 4701-4707. (Pubitemid 36857723)
6. Chu S, Allen L, Tinisha M, David S, Stephen F, Ravi B. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib treatment for 5 years. Blood (ASH Annu Meet Abstr) 2008; 112: 194
7. Weisberg E, Manley PW, Breitenstein W, Broggen J, Cowan-Jacob SW, Ray A et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129-141. (Pubitemid 40248339)
8. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399-401. (Pubitemid 38938156)
9. Nicaise C, Wang X, Roy A, Pfister M, Chen T-T, Bleickardt E et al. Dasatinib pharmacokinetics and exposure-response: relationships to efficacy and safety in patients with chronic myelogenous leukemia in chronic phase (CML-CP). Haematologica (EHA Annu Meet Abstr) 2008; 93: 227.
10. Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006; 107: 4532-4539. (Pubitemid 43801382)
11. Jorgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 2007; 109: 4016-4019. (Pubitemid 46641755)
12. Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029-1035.
13. Gajate C, Mollinedo F. The antitumor ether lipid ET-18-OCH(3) induces apoptosis through translocation and capping of Fas/CD95 into membrane rafts in human leukemic cells. Blood 2001; 98: 3860-3863.
14. Copland M, Pellicano F, Richmond L, Allan EK, Hamilton A, Lee FY et al. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 2008; 111: 2843-2853.
15. Pellicano F, Copland M, Jorgensen HG, Mountford J, Leber B, Holyoake TL. BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38-cells, through activation of protein kinase Cbeta. Blood 2009; 114: 4186-4196.
16. Jorgensen HG, Allan EK, Graham SM, Godden JL, Richmond L, Elliott MA et al. Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro. Leukemia 2005; 19: 1184-1191. (Pubitemid 40946002)
17. Nguyen TK, Rahmani M, Harada H, Dent P, Grant S. MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825. Blood 2007; 109: 4006-4015. (Pubitemid 46641754)
18. Yu C, Krystal G, Varticovksi L, McKinstry R, Rahmani M, Dent P et al. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res 2002; 62: 188-199. (Pubitemid 34074004)
19. Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 2005; 23: 5281-5293. (Pubitemid 46206982)
20. Barrett SD, Bridges AJ, Dudley DT, Saltiel AR, Fergus JH, Flamme CM et al. The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg Med Chem Lett 2008; 18: 6501-6504.
21. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319-325.
22. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
23. Matallanas D, Arozarena I, Berciano MT, Aaronson DS, Pellicer A, Lafarga M et al. Differences on the inhibitory specificities of H-Ras, K-Ras, and N-Ras (N17) dominant negative mutants are related to their membrane microlocalization. J Biol Chem 2003; 278: 4572-4581. (Pubitemid 36800954)
24. Cowley S, Paterson H, Kemp P, Marshall CJ. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 1994; 77: 841-852. (Pubitemid 24187682)
25. Coffer PJ, Koenderman L, de Groot RP. The role of STATs in myeloid differentiation and leukemia. Oncogene 2000; 19: 2511-2522. (Pubitemid 30339207)
26. Okutani Y, Kitanaka A, Tanaka T, Kamano H, Ohnishi H, Kubota Y et al. Src directly tyrosine-phosphorylates STAT5 on its activation site and is involved in erythropoietin-induced signaling pathway. Oncogene 2001; 20: 6643-6650. (Pubitemid 32980292)
27. Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K et al. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 2005; 105: 3303-3311.
28. Copland M, Hamilton A, Allan EK, Brunton V, Holyoake TL. BMS-214662 targets quiescent chronic myeloid leukaemia stem cells and enhances the activity of both imatinib and dasatinib (BMS-354825). Blood (ASH Annu Meet Abstr) 2005; 106: 693.
29. Holyoake T, Jiang X, Eaves C, Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 1999; 94: 2056-2064. (Pubitemid 29430422)
30. Fukuchi Y, Kizaki M, Yamato K, Kawamura C, Umezawa A, Hata J et al. Mcl-1, an early-induction molecule, modulates activin Ainduced apoptosis and differentiation of CML cells. Oncogene 2001; 20: 704-713. (Pubitemid 32179339)
31. Yu C, Rahmani M, Almenara J, Subler M, Krystal G, Conrad D et al. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and-resistant Bcr/Abl+ human myeloid leukemia cells. Cancer Res 2003; 63: 2118-2126. (Pubitemid 36538615)